Introduction {#j_iss-2017-0049_s_001}
============

Colorectal cancer (CRC) is a prevalent challenge in healthcare with 447,000 new cases and 215,000 deaths in 2012 in Europe \[[@j_iss-2017-0049_ref_001]\]. With changing treatment options for all kinds of cancer, it is now the second most common cancer for men and women in terms of mortality, only second to lung cancer \[[@j_iss-2017-0049_ref_001]\]. The majority of patients suffer from colon cancer, whereas approximately a third of patients present with rectal cancer \[[@j_iss-2017-0049_ref_002]\], although this number is quite variable throughout the literature. Five-year survival for CRC has improved over the last 30 years, ranging from around 50% in 1975 to 66% in 2012, for all stages \[[@j_iss-2017-0049_ref_002]\], \[[@j_iss-2017-0049_ref_003]\]. One part of this improvement is attributable to superior imaging techniques and early detection, leading to a more patient-oriented, tailored therapy compared to earlier times \[[@j_iss-2017-0049_ref_004]\]. As anatomy, lymphatic and vascular drainage, and therapeutic options of colon cancer differ significantly from the ones of rectal cancer, the imaging techniques of these two entities will be covered separately. In rectal cancer, an exact locoregional staging is essential \[[@j_iss-2017-0049_ref_005]\], whereas in colon cancer, other challenges like ruling out a second cancer proximal to a stenosing tumor play a more important role \[[@j_iss-2017-0049_ref_006]\]. For both rectal and colon cancer, ruling out metastatic disease prior to a potentially curative surgical approach is mandatory. This review will give an overview of current imaging techniques and their applications in early to advanced stages of colon and rectal cancer, allowing the clinicians to offer a personalized approach for each patient.

General imaging/staging principles {#j_iss-2017-0049_s_001_s_001}
----------------------------------

In patients suspected of having colon or rectal cancer, a detailed physical examination, family history, and measurement of the carcinoembryonic antigen (CEA) level is recommended \[[@j_iss-2017-0049_ref_005]\]. Usually, the first examination performed is optical colonoscopy (OC) with localization of the tumor and subsequent biopsy, and also to rule out other primary colonic tumors. In cases of incomplete colonoscopy, computed tomography (CT) colonography (CTC) can be performed to visualize tumors orally to a nonpassable stenosis. The sensitivity to detect colon cancer is similar for OC and CTC, ranging around 95% \[[@j_iss-2017-0049_ref_007]\]. However, one of the advantages of OC is to subsequently biopsy a lesion, which leads to a primary recommendation for OC over CTC. CTC is considered as a viable second-line option in patients, where the lesion could not be reached by OC or who do have contraindications for OC \[[@j_iss-2017-0049_ref_008]\], \[[@j_iss-2017-0049_ref_009]\]. Barium enema is considered as the last method of choice, if neither OC nor CTC is available to locate the tumor \[[@j_iss-2017-0049_ref_010]\]. CTC will be covered in more detail in a later paragraph.

Once the diagnosis of colon or rectal cancer is ascertained, staging should be performed using the latest version of the American Joint Committee on Cancer (AJCC) tumor, node, and metastasis (TNM) classification \[[@j_iss-2017-0049_ref_011]\]. As of January 2018, the reference standard will be the 8th edition, which is provided in an abbreviated form in [Table 1](#j_iss-2017-0049_tab_001){ref-type="table"}. Changes from the 7th edition are minuscule for CRC and affect mostly details relevant for histopathological staging \[[@j_iss-2017-0049_ref_011]\]. The only change significant for pretherapeutic imaging is the introduction of the M1c stage in patients with peritoneal carcinomatosis.

###### 

TNM staging of colon and rectal cancer.

  --------- -------------------------------------------------------------------------------------------------------
  T stage   
   T0       No evidence of primary tumor
   Tis      Carcinoma *in situ*
   T1       Tumor invades the submucosa
   T2       Tumor invades the muscularis propria
   T3       Tumor invades into pericolorectal tissues:
    T3a     Invasion ≤1 mm
    T3b     Invasion 1--5 mm
    T3c     Invasion ≥6--15 mm
    T3d     Invasion ≥15 mm
   T4a      Tumor penetrates the visceral peritoneum
   T4b      Tumor invades into adjacent organs
  N stage   
   N0       No evidence of lymph node metastases
   N1a      Metastasis in one regional lymph node
   N1b      Metastases in 2--3 regional lymph nodes
   N1c      Tumor deposits in the subserosa or pericolic/perirectal tissues (not to be differentiated by imaging)
   N2a      Metastases in 4--6 regional lymph nodes
   N2b      Metastases in 7 or more regional lymph nodes
  M stage   
   M0       No distant metastases
   M1a      Metastases confined to one organ
   M1b      Metastases in more than one organ
   M1c      Metastases to the peritoneum with or without other organ involvement
  --------- -------------------------------------------------------------------------------------------------------

Colon cancer {#j_iss-2017-0049_s_002}
============

Specific imaging requirements for colon cancer {#j_iss-2017-0049_s_002_s_001}
----------------------------------------------

CT of the abdomen and thorax is the method of choice for staging in colon cancer \[[@j_iss-2017-0049_ref_005]\]. It should be performed as a multiphase contrast-enhanced CT, ideally with an arterial phase covering the liver and a venous phase covering the chest and the abdomen \[[@j_iss-2017-0049_ref_012]\]. It allows to identify the site of the tumor in most cases, bulky lymphadenopathy, ascites, profound carcinomatosis, and invasion into adjacent organs ([Figure 1](#j_iss-2017-0049_fig_001){ref-type="fig"}). Liver metastases \>1 cm and lung metastases can also be identified with an accuracy of up to 95% \[[@j_iss-2017-0049_ref_013]\] and benign lesions can be differentiated based on typical imaging appearances.

![Contrast-enhanced CT image with coronal reformation showing a T4 sigmoid cancer invading the urinary bladder (arrow).\
The intervening fat plane between the tumor and the bladder wall is obliterated, indicating the tumor infiltration.](iss-3-20170049-g001){#j_iss-2017-0049_fig_001}

It must be taken into account that CT has only moderate reliability for T and N staging in colon cancer, with accuracies ranging around 67% and 69%. Apart from T4 tumors, the subclassification of T stage and nodal stage does not change the surgical management and is, therefore, not required in the preoperative workup \[[@j_iss-2017-0049_ref_014]\], \[[@j_iss-2017-0049_ref_015]\], \[[@j_iss-2017-0049_ref_016]\]. Even T4 colon cancers will usually not receive neoadjuvant treatment unless metastatic disease is present; however, it is of critical importance to report this finding to the treating surgeon, in order to enable optimal presurgical planning. In a recent retrospective study, the subgroup of T4b patients also seemed to have improved survival after neoadjuvant chemotherapy \[[@j_iss-2017-0049_ref_017]\]. The concept to treat locally advanced, non-metastatic colon cancer with neoadjuvant chemotherapy is currently assessed in a large phase 3 trial with over 1000 patients, which has finished patient recruitment in late 2016 \[[@j_iss-2017-0049_ref_018]\]. It has to be noted, though, that patients with early T1 tumors might be amenable for local excisional strategies (endoscopic mucosal resection, endoscopic submucosal dissection) \[[@j_iss-2017-0049_ref_019]\]. These early stages cannot be identified with CT or magnetic resonance imaging (MRI) but require the use of endoscopic ultrasound (EUS), which will be covered in the section on rectal cancer.

Small liver metastases and small peritoneal deposits \<5 mm also require additional techniques to optimally stage the patient, if clinically indicated \[[@j_iss-2017-0049_ref_020]\]. An MRI of the liver with diffusion-weighted imaging and hepatocyte-specific contrast agent is mandatory for optimal assessment of liver metastases \<1 cm. This will be covered in the chapter on metastatic CRC.

The 18-fluorodexoy glucose (FDG) positron emission tomography (PET)/CT is currently not recommended in the primary staging of colon cancer due to lack of high-quality evidence of efficacy and cost effectiveness \[[@j_iss-2017-0049_ref_021]\].

Screening for polyps and early colon cancer {#j_iss-2017-0049_s_002_s_002}
-------------------------------------------

As more than 90% of CRC arise from benign precursors through an adenoma/carcinoma sequence, early detection of adenomatous polyps poses a way to either prevent the development of CRC or to allow treatment of cancer in its early phase \[[@j_iss-2017-0049_ref_022]\], \[[@j_iss-2017-0049_ref_023]\]. Nevertheless, screening programs are not readily accepted by the population \[[@j_iss-2017-0049_ref_024]\], or are not efficient enough, as is the case with fecal occult blood testing or barium enema \[[@j_iss-2017-0049_ref_025]\], \[[@j_iss-2017-0049_ref_026]\]. CTC is a well-validated technique to improve early detection of polyps and advanced adenomas \[[@j_iss-2017-0049_ref_008]\], \[[@j_iss-2017-0049_ref_027]\]. Sensitivities to detect advanced adenomas and cancer are comparable to OC \[[@j_iss-2017-0049_ref_028]\]. As its performance is clearly superior to that of the barium enema, CTC is now recommended as the radiological method of choice for the detection of colorectal neoplasia \[[@j_iss-2017-0049_ref_025]\]. Barium enema is no longer recommended for this indication. CTC is well tolerated by patients, safe, and also cost effective \[[@j_iss-2017-0049_ref_024]\], \[[@j_iss-2017-0049_ref_029]\]. Being available as a diagnostic option to OC, CTC has the potential to increase the overall participation in CRC screening. It was recently included in the US Preventive Services Task Force screening guidelines for CRC \[[@j_iss-2017-0049_ref_026]\]. However, in a joint statement of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) and the European Society for Gastrointestinal Endoscopy, CTC is not recommended as a primary screening tool for CRC, although it can be used as an optional screening examination, on an individual basis \[[@j_iss-2017-0049_ref_025]\]. Other techniques, like MR-colonography or plain abdominal CT, have inferior performance in the early detection of advanced adenomas or colon cancer and should, therefore, not be considered as the primary radiological technique in this situation \[[@j_iss-2017-0049_ref_030]\].

Technique of CTC {#j_iss-2017-0049_s_002_s_003}
----------------

As the sensitivity of standard abdominal CT to detect small intracolonic lesions is poor \[[@j_iss-2017-0049_ref_031]\], optimal visualization in CTC requires both luminal distension and catharsis to enhance lesion detection \[[@j_iss-2017-0049_ref_032]\]. The technical standards for CTC have been published in a consensus statement by the ESGAR in 2013 \[[@j_iss-2017-0049_ref_033]\]. Similar to OC, bowel preparation on the day before the exam is performed, and patients will also receive a small amount of oral contrast media in order to increase lesion conspicuity and to differentiate small lesions from residual stool. A CT scan of the abdomen is performed without intravenous (IV) contrast in the prone and supine position, in order to allow for better visualization of polyps immersed in fluid or for clarification of mucosal folds, etc., which might be just an effect of positioning. Before the scan, luminal distension is provided by air or CO~2~ that is applied endorectally. Two-dimensional (2D) and 3D reconstructions of the dataset are performed, allowing for standard interpretation of the abdominal CT scan as well as endoluminal "fly through" images, hence, the alias name virtual colonoscopy \[[@j_iss-2017-0049_ref_032]\], \[[@j_iss-2017-0049_ref_034]\] ([Figure 2](#j_iss-2017-0049_fig_002){ref-type="fig"}). As there is an intrinsically higher contrast between air and polypoid/cancerous lesions in the lumen of the colon, CTC can be performed with a lower radiation dose than a usual diagnostic CT scan. In addition, several dose-reduction algorithms, like iterative reconstruction, exist that will further decrease the radiation exposure, leading to scans in the low- to sub-millisievert -- range \[[@j_iss-2017-0049_ref_035]\], \[[@j_iss-2017-0049_ref_036]\]. Dose reduction should not be pushed to the maximum possible, though, as the benefit of detecting colon cancer early outweighs the already low risk of radiation-induced carcinogenesis \[[@j_iss-2017-0049_ref_037]\].

![CT colonography after failed colonoscopy because of a stenosing rectosigmoidal cancer.\
(A) Sagittal CT image showing the tumor with a circular stenotic thickening of the rectal wall. (B) Surface rendered colon map with virtual colonoscopic pathway (green line) indicating a complete visualization of the large bowel. (C) Endoluminal 3D image at the level of the cecum. The appendix orifice is indicated by the arrow. No additional tumors were detected.](iss-3-20170049-g002){#j_iss-2017-0049_fig_002}

Diagnostic performance and limitations of CTC {#j_iss-2017-0049_s_002_s_004}
---------------------------------------------

According to several trials in this field, the sensitivity to detect colon cancer is equally good for CTC \[[@j_iss-2017-0049_ref_009]\] compared to OC \[[@j_iss-2017-0049_ref_031]\] (96% and 95%, respectively). For the detection of adenomatous polyps ≥10 mm, the sensitivity is also considered to be equal (CTC vs. OC, up to 94% vs. 98%) \[[@j_iss-2017-0049_ref_038]\]. Based on data from a recent meta-analysis, CTC also reaches comparable performance as OC in the detection of polyps/adenomas ≥6 mm in size (pooled analysis from seven trial CTC vs. OC, 73%--98% vs. 75%--93%). For lesions smaller than 6 mm, OC remains the superior technique in detection.

The performance of CTC can be affected by a number of pitfalls \[[@j_iss-2017-0049_ref_039]\], \[[@j_iss-2017-0049_ref_040]\]. As it was shown in some early CTC trials, suboptimal examination technique as well as interpretative errors by the radiologist can impair the performance of CTC \[[@j_iss-2017-0049_ref_041]\], \[[@j_iss-2017-0049_ref_042]\]. This can, however, effectively be avoided by performing the examination in adherence to technical standards and by dedicated CTC reader training \[[@j_iss-2017-0049_ref_033]\], \[[@j_iss-2017-0049_ref_043]\], \[[@j_iss-2017-0049_ref_044]\]. Last, the ability to endoscopically resect detected lesions and to obtain a tissue diagnosis is the reason why OC is still the method of choice for most clinicians.

Colonic visualization in patients with stenosing CRC {#j_iss-2017-0049_s_002_s_005}
----------------------------------------------------

Preoperative visualization of the entire colon and rectum is needed in patients with CRC for identification of synchronous colorectal neoplasia. CT colonography is recommended as the method of choice in patients with incomplete colonoscopy or with contraindications to colonoscopy \[[@j_iss-2017-0049_ref_025]\]. It is an effective and safe diagnostic option to complete colorectal visualization, if an obstructing CRC prevents complete colonoscopic assessment. Performed in a preoperative setting after failed colonoscopy, in patients with obstructing CRC, CTC has shown to be highly accurate in assessing synchronous CRC and advanced neoplasia \[negative predictive values (NPVs) of 100% and 97, respectively\] \[[@j_iss-2017-0049_ref_045]\]. CTC may further allow accurate segmental tumor location \[[@j_iss-2017-0049_ref_046]\] and, if performed after IV application of contrast media, the assessment of extracolonic abdominal organs \[[@j_iss-2017-0049_ref_025]\].

Rectal cancer {#j_iss-2017-0049_s_003}
=============

In rectal cancer, many of the principles described for colon cancer are also valid and should be followed in the primary workup of this condition. However, due to diverse treatment pathways that exist in rectal cancer, several locoregional risk factors have to be taken into account in order to correctly identify the risk for local or distant recurrence in patients suffering from rectal cancer \[[@j_iss-2017-0049_ref_047]\]. The primary diagnosis of rectal cancer is often more straightforward, either using digital rectal examination or office-based proctoscopy without the need of an endoscopy suite. The modality of choice for locoregional staging in rectal cancer is MRI and EUS for specific cases \[[@j_iss-2017-0049_ref_005]\]. In 2012 and 2016, an expert panel of the ESGAR published guidelines on how MRI in rectal cancer should be performed and reported. It also helps radiologists and clinicians to follow a standardized approach on how rectal cancer should be staged before treatment \[[@j_iss-2017-0049_ref_048]\].

Similar to colon cancer, all patients should receive a full OC to rule out second colon cancers and a CT of the abdomen and thorax, in order to detect or rule out metastatic disease. Similarly, there is no indication for the routine use of FDG-PET/CT in the primary staging of rectal cancer \[[@j_iss-2017-0049_ref_005]\].

Endoscopic ultrasound {#j_iss-2017-0049_s_003_s_001}
---------------------

Endorectal ultrasound is the most accurate method to perform T staging in early T1 and T2 tumors. The accuracy to correctly identify the invasion depth of rectal tumors is up to 97% in expert hands \[[@j_iss-2017-0049_ref_049]\]; however, it drops considerably if used by less experienced operators \[[@j_iss-2017-0049_ref_050]\]. In order to identify patients amenable for local excision, EUS is the sole method to identify early T1 (sm1-3) tumors, as MRI's local resolution is too low to allow this differentiation \[[@j_iss-2017-0049_ref_048]\]. Also, the accuracy to differentiate between T1 and T2 tumors in MRI is not high enough. Therefore, the role of MRI to stage very early tumors is limited. The limitations of the EUS, though, are high-seated lesions and stenosing tumors, which might impede complete visualization of these lesions. Also, the limited field of view might not allow complete visualization of the mesorectal fascia (MRF) and detection of pathological lymph nodes outside the mesorectum. Furthermore, it is a bit more invasive and not well tolerated by all patients \[[@j_iss-2017-0049_ref_051]\].

MRI {#j_iss-2017-0049_s_003_s_002}
---

According to the 2016 ESGAR guidelines for imaging rectal cancer, MRI should be performed in all patients with rectal cancer \[[@j_iss-2017-0049_ref_048]\]. The method of choice is MRI with at least 1.5-Tesla field strength with an external phased-array coil. The use of an endorectal coil is no longer recommended. Because of the lack of robust evidence on this topic, there is no dedicated consensus whether spasmolytics or cleansing enema are needed prior to the examination \[[@j_iss-2017-0049_ref_048]\]. Some centers, including ours, are performing these adjunct measures in order to optimize image quality. The MRI protocol should include high-resolution T2-weighted sequences performed in three planes. For optimal evaluation of T stage, and hence prognostic stratification, the slice thickness should be no more than 3 mm with a high resolution ("matrix"), leading to a voxel size of 1 mm^3^ or less. Diffusion-weighted sequences are increasingly performed. They are especially required in restaging of rectal cancer after chemoradiotherapy (CRT). In short, these sequences show more or less density of tissue, by visualizing the impairment of the Brownian movement after applying several magnetic gradients. The less freely protons can move in tissue, the higher the signal will be, especially in dense tumor tissues, i.e. primary rectal cancer or remnant tumor after CRT. There is no general consensus about the use of IV contrast agents; however, we perform it regularly for research purposes and sometimes to better depict tumor borders. However, this is not endorsed by the current guidelines \[[@j_iss-2017-0049_ref_048]\].

Practical use of MRI {#j_iss-2017-0049_s_003_s_003}
--------------------

First, MRI can deliver anatomic information about the tumor location, the distance to the anal verge and sphincter complex, i.e. also puborectalis sling and levator muscles. For low-lying tumors, the radiologist should differentiate whether the internal sphincter, the intersphincteric fat plane, and/or the external sphincter is involved by the tumor, due to different surgical approaches possible in these situations \[[@j_iss-2017-0049_ref_052]\]. Furthermore, the general features of the tumor like whether it is bulky, flat, villous, etc., can be described. Moreover, the circular location (given on as, e.g. 1--3 o'clock in the axial orientation) can be provided, which might be helpful in the case of smaller tumors. For higher tumors in the upper third, the relation to the peritoneal reflection has to be taken into account as peritoneal spread might occur earlier than in lower rectal tumors. The surgical accessibility to the pelvis and tumor infiltration into adjacent organs can also be quickly identified. Tumor length measurements can give an estimation to the clinician about the tumor size; likewise, tumor volumetry or 3D measurements are also considered feasible \[[@j_iss-2017-0049_ref_005]\], \[[@j_iss-2017-0049_ref_048]\].

Next, the T stage is assessed, which can be done with an overall accuracy of around 70% \[[@j_iss-2017-0049_ref_053]\]. It is one of the most important stratification criteria on how primary rectal cancer should be treated. Early tumors (T1/sm1), which can potentially be treated by local excisional therapies, need additional staging with endorectal ultrasound, as MRI cannot reach this degree of anatomical resolution or differentiate whether a tumor reaches the submucosa or not with sufficiently high accuracy. All tumors that are of higher T stage have a rapidly increasing risk of lymph node metastases and will potentially be treated with a total mesorectal excision (TME) without pretreatment \[[@j_iss-2017-0049_ref_047]\]. In intermediate risk tumors (≤T3b, very low-lying T2, questionable nodal positivity), short-term radiation followed by TME or TME alone are both endorsed by the current guidelines \[[@j_iss-2017-0049_ref_047]\]. MRI is limited in the ability to discriminate between T3a and T2 tumors, mostly due to desmoplastic reaction in the mesorectal tissue adjacent to the tumor \[[@j_iss-2017-0049_ref_053]\]. EUS has the same limitations as MRI; however, prognostically, there is no significant difference between T3a and T2 tumors. Thus, at least in the European guidelines, treatment will not be different for these early T3 stages compared to that of T2 (TME with or without short-term RT) \[[@j_iss-2017-0049_ref_047]\]. It has to be noted, though, that even in Europe, large geographical variations exist regarding the selection of neoadjuvant therapy in rectal cancer.

Tumors that reach more deeply into the mesorectum (T3c or higher, [Figure 3A](#j_iss-2017-0049_fig_003){ref-type="fig"}), and especially those which reach the mesorectal fascia (MRF, [Figure 3B](#j_iss-2017-0049_fig_003){ref-type="fig"}), will exhibit a higher risk for local treatment failure, independently of lymph node status. MRI is the gold standard to assess MRF endangerment of invasion; EUS is less accurate due to limited signal transmission and the difficulty in visualizing the entire MRF in many tumors \[[@j_iss-2017-0049_ref_054]\], \[[@j_iss-2017-0049_ref_055]\]. If the MRF is involved on MRI (distance of nearest tumor or lymph node ≤1 mm), the likelihood of a possible circumferential resection margin after TME is high. Therefore, they should receive long-term chemoradiotherapy followed by TME after tumor board decision \[[@j_iss-2017-0049_ref_047]\]. In expert hands, the capability of MRI to predict an endangered (≤1-mm distance to the tumor) or involved MRF is very good with a 92% concordance with pathology. A negative, i.e. clear MRF can be predicted with an NPV of 94% \[[@j_iss-2017-0049_ref_055]\]. In general, the penetration depth into the mesorectum measured by MRI is considered equivalent to pathology and should, therefore, be mentioned in the MRI report \[[@j_iss-2017-0049_ref_048]\]. CT has a role in assessing a negative MRF in patients that cannot receive MRI, but it is only reliable in mid- and upper third tumors \[[@j_iss-2017-0049_ref_056]\]. FDG/PET CT did not show any additional benefit in the local staging of rectal cancer and should have no role in the routine setting \[[@j_iss-2017-0049_ref_057]\].

![MRI in rectal cancer, T-stage and mesorectal fascia (MRF) assessment.\
(A) Transverse T2-weighted MRI image showing a T4a tumor that invades far into the dorsal mesorectum, invades the MRF (dashed line) and extends into the presacral fat plane. (B) Sagittal T2-weighted MRI image showing invasion of the posterior MRF, as indicated by arrows. This patient is of high risk for lokal recurrence despite the favorable tumor location in the mid/upper third of the rectum.](iss-3-20170049-g003){#j_iss-2017-0049_fig_003}

Assessment of lymph node metastases {#j_iss-2017-0049_s_003_s_004}
-----------------------------------

The general sensitivity and accuracy to correctly identify lymph node metastases with MRI is unfortunately quite low. Unlike other gastrointestinal malignancies, size criteria are unreliable (positive predictive value 62%) because up to 50% of metastatic lymph nodes are 5 mm or less in the short-axis diameter \[[@j_iss-2017-0049_ref_049]\]. The additional assessment of shape, border, and signal heterogeneity can help in the assessment; however, it still remains far from being accurate. Twenty-five percent of lymph nodes are overstaged on MRI, which might trigger unnecessary preoperative treatment in these patients \[[@j_iss-2017-0049_ref_048]\].

Therefore, risk assessment based on questionable lymph node metastases should be performed with caution, especially as ≤T3b tumors have a favorable prognosis and local control rate, irrespective of nodal stage \[[@j_iss-2017-0049_ref_058]\]. Special attention should also be paid to pelvic side wall lymph nodes or lymph nodes in the obturator fossa. These lymph nodes are outside the TME resection plane and also outside the standard radiation field, so the chance that they are left untreated remains high if not specifically addressed in the report. In a recent multicenter randomized trial from Japan, the importance of lateral lymph node dissection was highlighted. Patients with initially no lateral lymph node enlargement had a higher local recurrence rate (12.6% vs. 7.4%) if lateral nodes were not dissected, although 5-year overall survival and recurrence-free survival was not different \[[@j_iss-2017-0049_ref_059]\]. It has to be noted though that although several studies from Asian centers demonstrated the safety and efficacy of this procedure \[[@j_iss-2017-0049_ref_060]\], it is not widely accepted in European and US centers, which might be due to demographic differences in the patient cohorts.

Extramural vascular invasion {#j_iss-2017-0049_s_003_s_005}
----------------------------

An additional risk factor is the presence of extramural vascular invasion (EMVI). This feature is present when tumor signal is seen within a vessel that expands the vessel or leads to an irregular vascular contour ([Figure 4](#j_iss-2017-0049_fig_004){ref-type="fig"}). This observation can be made especially in patients that present with synchronous liver metastases (odds ratio, 5.7), but it has also been shown that these patients are of increased risk to develop distant metastases in the follow-up (odds ratio, 3.9) \[[@j_iss-2017-0049_ref_061]\]. Hence, there is a discussion whether these patients might be candidates for upfront chemotherapy. However, this is still under debate. Also, the presence of EMVI can be determined with a graded scale, therefore, gauging the diagnostic confidence of this frequently underreported finding \[[@j_iss-2017-0049_ref_062]\]. The presence or absence of EMVI should now be reported at the primary staging and at restaging, although it has been shown that MRI tends to overstage EMVI after CRT \[[@j_iss-2017-0049_ref_005]\], \[[@j_iss-2017-0049_ref_048]\], \[[@j_iss-2017-0049_ref_063]\].

![EMVI.\
(A) Coronal T2-weighted MRI image showing longitudinal vascular expansion with intraluminal tumor signal (arrow). This sign is highly predictive of synchronous or metachronous liver metastases as shown in the transverse F18-FDG PET/MR image (fused T1-gradient echo sequence with fat suppression and PET) of the same patient (B).](iss-3-20170049-g004){#j_iss-2017-0049_fig_004}

With these parameters, a pre-therapeutical risk stratification is possible, which is summarized in [Figure 5](#j_iss-2017-0049_fig_005){ref-type="fig"}. Of note, these recommendations were made by the European Society of Medical Oncology (ESMO). Several minor discrepancies exist between them and recommendations for risk-adapted treatment from other societies in this field. To cover all these differences is certainly beyond the scope of this manuscript.

![ESMO guidelines for the risk assessment in rectal cancer prior to treatment.](iss-3-20170049-g005){#j_iss-2017-0049_fig_005}

Response to neoadjuvant treatment {#j_iss-2017-0049_s_003_s_006}
---------------------------------

Another important and difficult application is restaging after neoadjuvant chemoradiotherapy in high-risk patients. This is usually performed 6--8 weeks after the end of the treatment, allowing for the possibility of a prolonged effect of radiation \[[@j_iss-2017-0049_ref_048]\]. Restaging with MRI should be performed at this stage and before a surgical procedure, as the surgical approach might be different in the case of a good response, and organ-sparing resections might be an option. Furthermore, the likelihood for complete pathological response (pCR) after CRT is around 25%, and these patients might be candidates for a watch-and-wait strategy, which is currently investigated in trials \[[@j_iss-2017-0049_ref_064]\], \[[@j_iss-2017-0049_ref_065]\]. The conventional T2-weighted sequences are insufficient to assess for residual tumors, which has been shown in a recent meta-analysis. Therefore other techniques, like diffusion-weighted imaging, have to be applied to improve the sensitivity from 50% to around 80% \[[@j_iss-2017-0049_ref_066]\] ([Figure 6](#j_iss-2017-0049_fig_006){ref-type="fig"}).

![Restaging of rectal cancer after CRT with MRI.\
(A) Transverse T2-weighted MR image showing a semi-circumferential tumor in the 7--1 o'clock position; (B+C): transverse diffusion-weighted image with a b-value of 800 s/mm^2^ (B) and ADC map (C). There is a marked diffusion restriction, i.e. low apparent diffusion coefficient indicated by a dark signal within the rectal lesion; (D--F) similar sequences like (A--C); after long-course chemoradiotherapy, the tumor has decreased in size with questionable residual mesorectal infiltration; (E+F) no clearly increased signal on the b-800 image, but a focal area of dark signal (white arrow) on the ADC map indicates residual tumor, with a higher sensitivity than T2-weighted sequences.](iss-3-20170049-g006){#j_iss-2017-0049_fig_006}

Apart from an assessment with MRI, patients need a clinical and endoscopic reassessment, as only the combination of all the three parameters has the best accuracy to rule out residual tumor. The post-test probability of all the three modalities combined reaches 98%. However, in 15%, when a residual tumor is suspected, the finding is actually over-interpreted, and the tumor is already pCR. MRI also plays a role in the follow-up of patients who underwent organ-sparing local excision and who are watched with a clinical pathological response \[[@j_iss-2017-0049_ref_067]\]. Up to 25% of the recurrences appear below the mucosa or in the mesorectum and might be missed with endoscopic assessment only \[[@j_iss-2017-0049_ref_064]\].

Workup of metastatic colorectal cancer {#j_iss-2017-0049_s_003_s_007}
--------------------------------------

At primary staging, all patients with colon or rectal cancer should receive a CT of the abdomen and chest, although an X-ray of the chest to assess for metastases is generally considered feasible by the guidelines \[[@j_iss-2017-0049_ref_005]\], \[[@j_iss-2017-0049_ref_068]\]. In our practice, though, we do not rely on chest X-ray in the staging and restaging process due to the poor visualization of smaller lung metastases \[[@j_iss-2017-0049_ref_069]\]. As resection of lung metastases is a valid element in the multimodal treatment concept of CRC lung metastases, we perform chest CT routinely for our patients. Although there is no evidence of improved survival in the follow-up after CRC resection \[[@j_iss-2017-0049_ref_070]\], we do think that lung resection is generally underused, as we see several patients every week who might have been candidates for lung resection if presented to a thoracic surgeon at earlier times. These patients should regularly be re-evaluated in tumor boards, and this will only be possible in the case of optimal staging information. With modern scanners, radiation exposure becomes of less concern, and the reliability of the examination is greatly enhanced. For the detection of liver metastases ≥1 cm, contrast-enhanced CT is considered equal to liver MRI; however, the sensitivity drops considerably for smaller lesions, which might be important if a liver resection is considered \[[@j_iss-2017-0049_ref_020]\]. Liver steatosis or steatohepatitis as a side effect of neoadjuvant chemotherapy, i.e. chemotherapy-associated steatohepatitis (CASH) leads to a decreased detection rate of liver metastases as well \[[@j_iss-2017-0049_ref_071]\]. Therefore, in all patients that are potential candidates for liver resection, we endorse MRI with hepatocyte-specific contrast agents and diffusion-weighted imaging, as this has been shown to be the most accurate staging also for small liver metastases \[[@j_iss-2017-0049_ref_072]\] ([Figure 7](#j_iss-2017-0049_fig_007){ref-type="fig"}). Of note, this procedure is only suitable to assess patients that might be amenable for liver resection. If there is extensive metastatic disease, frank peritoneal disease, bone metastases, or other reason why a curative resection cannot be performed, a CT scan is sufficient to follow for treatment response on palliative chemotherapy \[[@j_iss-2017-0049_ref_005]\]. The use of PET/CT is still debated controversially in metastatic CRC. Although it has been shown in a recent randomized trial in patients with potentially resectable liver metastases that the change in management by PET/CT was minuscule with 8% \[[@j_iss-2017-0049_ref_073]\], other meta-analyses suggest a higher number of extra-hepatic findings that were only picked up in PET/CT and changed management of patients \[[@j_iss-2017-0049_ref_074]\]. Currently, there is no clear recommendation for the use of PET/CT in metastatic patients. At our center, we use it in difficult cases in which the presence of extrahepatic disease might distinguish between a potentially curative/resectable treatment approach.

![Multimodality staging of metastatic CRC: male patients with oligometastatic CRC scheduled for multiple atypical liver resections (not all hepatic lesions are shown on these images).\
(A+B) Transverse CT image in the arterial (A) and portal-venous phase (B). A hypervascular lesion is seen in Segment VII, which is only faintly visible on the portal venous phase. In this region, no other metastases are visible. (C--E) MRI with DWI and hepatobiliary-phase imaging demonstrates an additional lesion (D), which changes the surgical management. (C+D) Axial DWI image with high b-value (600 s/mm^2^). An additional lesion more medial in Segment VII is visualized (D). (E) Transverse T1-gradient echo sequence with fat suppression 20-min post injection of gadoxetic acid shows both lesions on the same image.](iss-3-20170049-g007){#j_iss-2017-0049_fig_007}

Follow-up of colorectal cancer {#j_iss-2017-0049_s_003_s_008}
------------------------------

There are limited data about the correct interval and frequency of imaging studies in the follow-up of colon and rectal cancer, similar to recommendations for clinical follow-up \[[@j_iss-2017-0049_ref_006]\], \[[@j_iss-2017-0049_ref_047]\], \[[@j_iss-2017-0049_ref_056]\], \[[@j_iss-2017-0049_ref_068]\]. There is some weak consensus to perform MRI in the follow-up after local excision of early rectal cancers; however, it is unclear, how frequent these examinations should be performed \[[@j_iss-2017-0049_ref_005]\]. At our institution, we perform a tight follow-up in the first 2--3 years with 3--6 monthly CT of the chest and abdomen, as well as pelvic MRI if a higher risk for local recurrence is suspected. This interval increases to 6--12 monthly, up until 5 years. After 5 years, patients are further followed-up on an individual basis.
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